PUBLISHER: Acute Market Reports | PRODUCT CODE: 1422211
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1422211
Ankylosing Spondylitis Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine, causing pain, stiffness, and impaired mobility. The ankylosing spondylitis market is expected to grow at a CAGR of 8.5% during the forecast period of 2024 to 2032, propelled by advancements in biological therapies, a patient-centric approach with support programs, and increasing awareness leading to early diagnosis. However, the high cost of biologic therapies poses a notable restraint. Market segmentation reflects the dynamic preferences for AS drugs and regional variations in disease prevalence. Geographically, North America contributes significantly to revenue, while the Asia-Pacific region presents high growth potential. Competitive trends highlight the strategies adopted by major players, including Novartis, AbbVie, and Janssen. These companies leverage innovation, patient support, and global market expansion to maintain a competitive edge. As the ankylosing spondylitis market progresses from 2023 to the forecast period of 2032, addressing cost barriers, sustaining patient-centric approaches, and adapting to regional nuances will be critical for continued success in improving the lives of individuals affected by this chronic inflammatory condition.
Advancements in Biologic Therapies
Advances in biologic therapies, such as TNF inhibitors, have significantly contributed to the treatment landscape of ankylosing spondylitis. Medications like Cosentyx, Humira, and Enbrel have shown efficacy in reducing inflammation, managing symptoms, and improving the overall quality of life for AS patients. The evidence lies in clinical trials and real-world studies that showcase the positive impact of these biological therapies. For instance, studies demonstrate the effectiveness of Cosentyx in achieving sustained improvement in AS symptoms and functionality. As these biologics continue to be at the forefront of AS treatment, their ongoing development and adoption contribute to the market's growth.
Patient-Centric Approach and Support Programs
A patient-centric approach, coupled with comprehensive support programs provided by pharmaceutical companies, has become a driving force in the ankylosing spondylitis market. Companies offering AS treatments, such as Simponi, Remicade, and Cimzia, have initiated support programs to assist patients in accessing medications, managing side effects, and adhering to treatment plans. The evidence lies in patient testimonials and real-world experiences that highlight the positive impact of these support programs on treatment adherence and patient outcomes. As companies continue to prioritize patient well-being and holistic care, the patient-centric approach is anticipated to play a pivotal role in sustaining the market's growth.
Increasing Awareness and Early Diagnosis
The growing awareness of ankylosing spondylitis and efforts to achieve early diagnosis have positively influenced the market. Initiatives by healthcare organizations, patient advocacy groups, and pharmaceutical companies have contributed to increased awareness about the disease's symptoms and the importance of early intervention. The evidence lies in the rise in diagnosed cases and the implementation of screening programs that aim to identify AS at an early stage. Early diagnosis allows for timely intervention and the initiation of effective treatments, leading to better disease management. As awareness campaigns continue to educate both healthcare professionals and the general public, the trend toward early diagnosis is expected to persist, fostering the growth of the AS market.
High Cost of Biologic Therapies
The high cost associated with biologic therapies for ankylosing spondylitis poses a significant restraint on market accessibility. Despite their effectiveness, medications like Cosentyx and Humira come with a substantial financial burden for both patients and healthcare systems. The evidence lies in economic evaluations and studies that highlight the cost-effectiveness challenges of biological treatments. The financial strain may lead to limited access for some patients, potentially hindering optimal disease management. While patient assistance programs exist, addressing the overarching issue of the high cost of biologics is crucial for ensuring equitable access to effective AS treatments.
Drug Segmentation: Cosentyx, Humira, and Enbrel Dominate the Market
In 2023, the ankylosing spondylitis market saw the highest revenue from drugs such as Cosentyx, Humira, and Enbrel. However, the highest Compound Annual Growth Rate (CAGR) during the forecast period (2024-2032) is anticipated from Cimzia. This dynamic growth is driven by the specific attributes and evolving preferences of patients and healthcare providers. Studies and real-world evidence support the efficacy of Cimzia in managing AS symptoms and improving patient outcomes. As the landscape of AS treatment evolves, drug preferences may shift, influenced by factors such as safety profiles and patient response.
North America Remains the Global Leader
Geographically, North America contributed the highest revenue percentage in 2023, reflecting the well-established healthcare infrastructure and high prevalence of ankylosing spondylitis cases. However, the Asia-Pacific region is poised to exhibit the highest CAGR during the forecast period. The evidence lies in the increasing awareness of AS, improving healthcare access, and the evolving landscape of treatment options in Asia-Pacific countries. These geographic trends emphasize the need for tailored strategies to address regional variations in disease prevalence, treatment preferences, and healthcare infrastructure.
Market Competition to Intensify during the Forecast Period
In 2023, major players in the ankylosing spondylitis market included Novartis, AbbVie, Janssen, Amgen, UCB, Pfizer, Inc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Merck & Co., Inc., and others. These companies adopted diverse strategies, including research and development, patient support initiatives, and market expansion efforts. The evidence lies in the continuous development of new treatment options, patient assistance programs, and collaborations with healthcare professionals and patient advocacy groups. As of 2023, the competitive landscape indicates a dynamic market where companies strive to enhance their offerings and support systems. Revenues for 2023 and the expected landscape for the forecast period (2024-2032) reveal a competitive environment where innovation, patient-centered approaches, and global strategies are key determinants of success.
Historical & Forecast Period
This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofAnkylosing Spondylitis market are as follows:
- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report:
Micro and macro environment factors that are currently influencing the Ankylosing Spondylitis market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Drug
- Cosentyx
- Humira
- Simponi
- Remicade
- Enbrel
- Cimzia
- Others
Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
Region Segment (2021-2031; US$ Million)
- North America
- U.S.
- Canada
- Rest of North America
- UK and European Union
- UK
- Germany
- Spain
- Italy
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC
- Africa
- Rest of Middle East and Africa
Key questions answered in this report:
- What are the key micro and macro environmental factors that are impacting the growth of Ankylosing Spondylitis market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2031.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Ankylosing Spondylitis market?
- Which is the largest regional market for Ankylosing Spondylitis market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Ankylosing Spondylitis market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Ankylosing Spondylitis market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Ankylosing Spondylitis Market
- 2.2. Global Ankylosing Spondylitis Market, By Drug, 2023 (US$ Million)
- 2.3. Global Ankylosing Spondylitis Market, By Distribution Channel, 2023 (US$ Million)
- 2.4. Global Ankylosing Spondylitis Market, By Geography, 2023 (US$ Million)
- 2.5. Attractive Investment Proposition by Geography, 2023
3. Ankylosing Spondylitis Market: Competitive Analysis
- 3.1. Market Positioning of Key Ankylosing Spondylitis Market Vendors
- 3.2. Strategies Adopted by Ankylosing Spondylitis Market Vendors
- 3.3. Key Industry Strategies
- 3.4. Tier Analysis 2023 Versus 2032
4. Ankylosing Spondylitis Market: Macro Analysis & Market Dynamics
- 4.1. Introduction
- 4.2. Global Ankylosing Spondylitis Market Value, 2022 - 2032, (US$ Million)
- 4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
- 4.4. Impact Analysis of Drivers and Restraints
- 4.5. See-Saw Analysis
- 4.6. Porter's Five Force Model
- 4.6.1. Supplier Power
- 4.6.2. Buyer Power
- 4.6.3. Threat Of Substitutes
- 4.6.4. Threat Of New Entrants
- 4.6.5. Competitive Rivalry
- 4.7. PESTEL Analysis
- 4.7.1. Political Landscape
- 4.7.2. Economic Landscape
- 4.7.3. Technology Landscape
- 4.7.4. Legal Landscape
- 4.7.5. Social Landscape
5. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2023 Versus 2032
- 5.3. Volume and Pricing Analysis, 2022-2032
- 5.4. Market Segmentation
- 5.4.1. Cosentyx
- 5.4.2. Humira
- 5.4.3. Simponi
- 5.4.4. Remicade
- 5.4.5. Enbrel
- 5.4.6. Cimzia
- 5.4.7. Others
6. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 6.1. Market Overview
- 6.2. Growth & Revenue Analysis: 2023 Versus 2032
- 6.3. Volume and Pricing Analysis, 2022-2032
- 6.4. Market Segmentation
- 6.4.1. Hospital pharmacy
- 6.4.2. Retail pharmacy
- 6.4.3. Online pharmacy
7. North America Ankylosing Spondylitis Market, 2022-2032, USD (Million)
- 7.1. Market Overview
- 7.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 7.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 7.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
- 7.4.1.North America
- 7.4.1.1. U.S.
- 7.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 7.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 7.4.1.2. Canada
- 7.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 7.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 7.4.1.3. Rest of North America
- 7.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 7.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 7.4.1.1. U.S.
- 7.4.1.North America
8. UK and European Union Ankylosing Spondylitis Market, 2022-2032, USD (Million)
- 8.1. Market Overview
- 8.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 8.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
- 8.4.1.UK and European Union
- 8.4.1.1. UK
- 8.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 8.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.4.1.2. Germany
- 8.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 8.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.4.1.3. Spain
- 8.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 8.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.4.1.4. Italy
- 8.4.1.4.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 8.4.1.4.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.4.1.5. France
- 8.4.1.5.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 8.4.1.5.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.4.1.6. Rest of Europe
- 8.4.1.6.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 8.4.1.6.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.4.1.1. UK
- 8.4.1.UK and European Union
9. Asia Pacific Ankylosing Spondylitis Market, 2022-2032, USD (Million)
- 9.1. Market Overview
- 9.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 9.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
- 9.4.1.Asia Pacific
- 9.4.1.1. China
- 9.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 9.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.4.1.2. Japan
- 9.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 9.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.4.1.3. India
- 9.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 9.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.4.1.4. Australia
- 9.4.1.4.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 9.4.1.4.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.4.1.5. South Korea
- 9.4.1.5.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 9.4.1.5.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.4.1.6. Rest of Asia Pacific
- 9.4.1.6.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 9.4.1.6.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.4.1.1. China
- 9.4.1.Asia Pacific
10. Latin America Ankylosing Spondylitis Market, 2022-2032, USD (Million)
- 10.1. Market Overview
- 10.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 10.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
- 10.4.1.Latin America
- 10.4.1.1. Brazil
- 10.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 10.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.4.1.2. Mexico
- 10.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 10.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.4.1.3. Rest of Latin America
- 10.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 10.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.4.1.1. Brazil
- 10.4.1.Latin America
11. Middle East and Africa Ankylosing Spondylitis Market, 2022-2032, USD (Million)
- 11.1. Market Overview
- 11.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 11.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
- 11.4.1.Middle East and Africa
- 11.4.1.1. GCC
- 11.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 11.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.4.1.2. Africa
- 11.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 11.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.4.1.3. Rest of Middle East and Africa
- 11.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
- 11.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.4.1.1. GCC
- 11.4.1.Middle East and Africa
12. Company Profile
- 12.1. Novartis
- 12.1.1. Company Overview
- 12.1.2. Financial Performance
- 12.1.3. Product Portfolio
- 12.1.4. Strategic Initiatives
- 12.2. AbbVie
- 12.2.1. Company Overview
- 12.2.2. Financial Performance
- 12.2.3. Product Portfolio
- 12.2.4. Strategic Initiatives
- 12.3. Janssen
- 12.3.1. Company Overview
- 12.3.2. Financial Performance
- 12.3.3. Product Portfolio
- 12.3.4. Strategic Initiatives
- 12.4. Amgen
- 12.4.1. Company Overview
- 12.4.2. Financial Performance
- 12.4.3. Product Portfolio
- 12.4.4. Strategic Initiatives
- 12.5. UCB
- 12.5.1. Company Overview
- 12.5.2. Financial Performance
- 12.5.3. Product Portfolio
- 12.5.4. Strategic Initiatives
- 12.6. Pfizer, Inc.
- 12.6.1. Company Overview
- 12.6.2. Financial Performance
- 12.6.3. Product Portfolio
- 12.6.4. Strategic Initiatives
- 12.7. Eli Lilly and Company
- 12.7.1. Company Overview
- 12.7.2. Financial Performance
- 12.7.3. Product Portfolio
- 12.7.4. Strategic Initiatives
- 12.8. Johnson & Johnson Services, Inc.
- 12.8.1. Company Overview
- 12.8.2. Financial Performance
- 12.8.3. Product Portfolio
- 12.8.4. Strategic Initiatives
- 12.9. Merck & Co., Inc.
- 12.9.1. Company Overview
- 12.9.2. Financial Performance
- 12.9.3. Product Portfolio
- 12.9.4. Strategic Initiatives
- 12.10. Other Notable Players
- 12.10.1. Company Overview
- 12.10.2. Financial Performance
- 12.10.3. Product Portfolio
- 12.10.4. Strategic Initiatives
List of Tables
- TABLE 1 Global Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 2 Global Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 3 North America Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 4 North America Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 5 U.S. Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 6 U.S. Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 7 Canada Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 8 Canada Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 9 Rest of North America Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 10 Rest of North America Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 11 UK and European Union Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 12 UK and European Union Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 13 UK Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 14 UK Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 15 Germany Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 16 Germany Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 17 Spain Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 18 Spain Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 19 Italy Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 20 Italy Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 21 France Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 22 France Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 23 Rest of Europe Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 24 Rest of Europe Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 25 Asia Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 26 Asia Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 27 China Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 28 China Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 29 Japan Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 30 Japan Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 31 India Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 32 India Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 33 Australia Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 34 Australia Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 35 South Korea Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 36 South Korea Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 37 Latin America Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 38 Latin America Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 39 Brazil Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 40 Brazil Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 41 Mexico Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 42 Mexico Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 43 Rest of Latin America Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 44 Rest of Latin America Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 45 Middle East and Africa Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 46 Middle East and Africa Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 47 GCC Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 48 GCC Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 49 Africa Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 50 Africa Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 51 Rest of Middle East and Africa Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
- TABLE 52 Rest of Middle East and Africa Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
List of Figures
- FIG. 1 Global Ankylosing Spondylitis Market: Market Coverage
- FIG. 2 Research Methodology and Data Sources
- FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
- FIG. 4 Global Ankylosing Spondylitis Market: Quality Assurance
- FIG. 5 Global Ankylosing Spondylitis Market, By Drug, 2023
- FIG. 6 Global Ankylosing Spondylitis Market, By Distribution Channel, 2023
- FIG. 7 Global Ankylosing Spondylitis Market, By Geography, 2023
- FIG. 8 Market Geographical Opportunity Matrix - Global Ankylosing Spondylitis Market, 2023
FIG. 9Market Positioning of Key Ankylosing Spondylitis Market Players, 2023
FIG. 10Global Ankylosing Spondylitis Market - Tier Analysis - Percentage of Revenues by Tier Level, 2023 Versus 2032
- FIG. 11 Global Ankylosing Spondylitis Market, By Drug, 2023 Vs 2032, %
- FIG. 12 Global Ankylosing Spondylitis Market, By Distribution Channel, 2023 Vs 2032, %
- FIG. 13 U.S. Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
- FIG. 14 Canada Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
- FIG. 15 Rest of North America Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
- FIG. 16 UK Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
- FIG. 17 Germany Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
- FIG. 18 Spain Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
- FIG. 19 Italy Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
- FIG. 20 France Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
- FIG. 21 Rest of Europe Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
- FIG. 22 China Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
- FIG. 23 Japan Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
- FIG. 24 India Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
- FIG. 25 Australia Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
- FIG. 26 South Korea Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
- FIG. 27 Rest of Asia Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
- FIG. 28 Brazil Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
- FIG. 29 Mexico Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
- FIG. 30 Rest of Latin America Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
- FIG. 31 GCC Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
- FIG. 32 Africa Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
- FIG. 33 Rest of Middle East and Africa Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
